IMP761, an experimental immunosuppressive therapy being developed by Immutep for multiple sclerosis (MS) and other autoimmune diseases, was well tolerated in healthy volunteers when given at single increasing doses. The findings come from the single-ascending dose portion of an ongoing Phase 1 clinical trial (NCT06637865), which tested IMP761 when administered intravenously (into the vein) at […]
The post Experimental MS treatment IMP761 found safe, well tolerated in Phase 1 trial appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com